Crossbow Therapeutics, Inc.

About Crossbow Therapeutics, Inc.

Crossbow Therapeutics is dedicated to revolutionizing cancer treatment by developing potent and precise antibody therapies that target a wide range of cancer antigens. Their mission is to cure cancer by expanding the reach and impact of immunotherapy, improving the lives of cancer patients through next-generation therapies like T-Bolt™ molecules.

Products & Services

CBX-250:A T-Bolt™ T Cell Engager targeting Cathepsin G for the treatment of myeloid malignancies such as AML, MDS, and CML.

CBX-663:A broadly acting therapeutic T-Bolt™ T Cell Engager targeting TERT for a wide range of solid and hematologic malignancies.

Specialties

Antibody Therapeutics Cancer Immunotherapy T-Cell Receptor Mimetics (TCRm) T-Bolt™ Molecules Cancer Antigen Targeting

Funding History

Debug: View Raw Funding Data

#	Type	Amount Fields	Date Fields	Investors
1	RT: Series A T: - FT: Series A	A: 80000000 MR: - FA: $80 million FAN: 80000000	D: 2023-07-11 FD: 2023-07-11	7 investors

Series A Latest

2023-07-11

$80.0M

7 investors (Pro only)

Growth Metrics

+45%

Employee Growth

YoY

3.2x

Funding Growth

Last Round

12

Markets

Operating

10K+

Customers

Active

View 3 more growth metrics with Pro

Unlock All Metrics

Mock Up

Team & Leadership

B

Briggs Morrison

Chief Executive Officer, President

LinkedIn (Pro only)

D

Dmitri Wiederschain

Chief Scientific Officer

LinkedIn (Pro only)

S

Shaliny Kushwaha

Senior Vice President, Head of Regulatory Affairs and Clinical Development Operations

LinkedIn (Pro only)

G

Geraldine Paulus

Co-founder, Senior Vice President, Head of Corporate Development and Operations

M

Michi Schebesta

Vice President, Head of Biology

B

Benjamin Lee

Senior Vice President, Head of Translational Medicine

View 18 more team members with Pro

Unlock Full Team Directory

Recent News